INNATECARES

INNATE CARES

HELPING YOU ACCESS THE CARE YOU NEED

If your doctor has prescribed LUMOXITI, you may have questions.

The InnateCares program can help. We can answer your questions about:

  • Insurance coverage for your medicine
  • Your out-of-pocket costs
  • Financial support
  • Pharmacies that stock or deliver your medicine
  • Nurse and other educational help

To learn more about the InnateCares program, please call 1-844-694-6628
 Monday – Friday, 8 AM – 8 PM EST

HOW INNATECARES CAN HELP

Questions about insurance and costs? Resources are available to help.

If your doctor has prescribed LUMOXITI, you may have questions. The InnateCares program can help. We can answer your questions about:

  • Insurance coverage
  • Out-of-pocket costs
  • Patient assistance programs

To receive help from InnateCares please phone 1-844-694-6628.

LUMOXITI AFFORDABILITY OPTIONS

Find different ways to help you pay for LUMOXITI

LUMOXITI Co-pay Savings Program

The LUMOXITI Co-pay Savings Program may help you pay a set amount of out-of-pocket costs.

Who can apply?

  • Patients who are covered by commercial insurance, and their insurance does not cover the full cost of their prescription
  • Residents of the United States or Puerto Rico
  • You are ineligible if prescriptions are paid by any state or Federally funded programs, including but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense, or TRICARE
  • Patients with a valid prescription to accompany the LUMOXITI Co-pay Savings Program offer

What to know

What happens once I’m enrolled in the LUMOXITI Co-pay Savings Program?

A Co-pay Savings Program account will be created for you. This can be done by the pharmacy, your doctor, or by calling an InnateCares representative. Once enrolled, you will continue to pay a set amount of your out-of-pocket costs for LUMOXITI. The pharmacy or your doctor will use the Co-pay Savings Program to cover the balance, up to the program maximum.

What are the specific costs associated with the LUMOXITI Co-pay Savings Program?

The patient pays $0 per infusion, program pays remaining out-of-pocket costs up to a maximum of $26,000 per year. The out-of-pocket costs covered by the program can include the cost of the product itself and/or the cost of infusion of the product (program maximum of $100 per infusion assistance). Patients who are residents of Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for infusion assistance.

What does the LUMOXITI Co-pay Savings Program cover?

The LUMOXITI Co-pay Savings Program covers the cost of the drug and administration but does not cover costs for office visits or any other associated costs.

Are there income requirements to participate in the program?

No. There are no income requirements to participate in the program.

Where can I find additional information?

For additional information, please call an InnateCares representative at 1-844-694-6628.

AZ&Me Prescription Savings Program


AZ&Me Prescription Savings Program provides AstraZeneca medicines at no cost if you qualify.

Who can apply?

  • People without health insurance
  • Medicare Part D and/or B recipients
  • Those who have recently experienced a financial crisis
  • Legal residents of the United States or Puerto Rico

What to know

Eligibility rules apply, please call an AZ&Me representative for more information at 1-800-AZandMe (1-800-292-6363).

Independent Patient Assistance Foundations

Assistance may be available through independent foundations such as those listed below. Foundations can provide a variety of assistance types: co-pay, transportation, premium, patient education, etc.

Who can apply?

These foundations are not associated with Innate Pharma; specific details and eligibility requirements can be found directly at the foundations’ websites.

Patient Access Network Foundation
www.PANfoundation.org
1-866-316-7263

Good Days Fund
www.mygooddays.org
1-877-968-7233

Patient Advocate Foundation
www.patientadvocate.org
1-800-532-5274

HealthWell Foundation
www.healthwellfoundation.org
1-800-675-8416

CancerCare Co-Payment Assistance Foundation
www.cancercare.org
1-866-552-6729

The Assistance Fund
www.theassistancefund.org
1-855-845-3663

Leukemia & Lymphoma Society
www.lls.org
1-800-955-4572

Patient Services, Inc.
www.patientservicesinc.org
1-800-366-7741

What to know

For additional information, please call an InnateCares representative at 1-844-694-6628 Monday – Friday, 8 AM – 8 PM EST.

Read More

IMPORTANT SAFETY INFORMATION

LUMOXITI can cause serious side effects, including:

  • Capillary Leak Syndrome (CLS). LUMOXITI can cause fluid to leak from small blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening if not treated right away. Get emergency medical help right away if you develop any of the following symptoms of CLS:
  • swelling of your face, arms, or legs
  • fast weight gain (increase in 5.5 pounds from Day 1 of your current cycle)
  • weakness or dizziness
  • shortness of breath or trouble breathing
  • cough
  • low blood pressure

Your healthcare provider will check your weight and blood pressure before you receive each dose of LUMOXITI and as needed during treatment.

  • Hemolytic Uremic Syndrome (HUS). Hemolytic uremic syndrome is a condition that affects your blood cells and kidneys and may be life-threatening if not treated right away. Get emergency medical help right away if you develop any of the following symptoms of HUS:
  • decrease in the amount of urine or dark urine (tea-colored)
  • unusual bleeding or bruising of your skin
  • stomach pain
  • vomiting
  • fever
  • feeling tired
  • changes in mood or behavior
  • confusion
  • seizures
  • shortness of breath
  • fast heartbeat

Your healthcare provider will do blood tests to check your blood cells and kidneys before you receive each dose of LUMOXITI and during treatment as recommended by your healthcare provider.

If you develop any of these symptoms of CLS or HUS, your healthcare provider may monitor you in the hospital.

Getting medical treatment right away may help keep these problems from becoming more serious.

Your healthcare provider will check you for these problems during your treatment with LUMOXITI. Your healthcare provider may delay or completely stop treatment with LUMOXITI if you have severe side effects.

LUMOXITI can cause other serious side effects, including:

  • Kidney problems. LUMOXITI may cause kidney problems. People who have HUS, are 65 years of age or older, or those who have kidney problems before starting treatment with LUMOXITI may have an increased risk of worse kidney problems after treatment with LUMOXITI. Tell your healthcare provider right away if you have any changes in the amount you urinate. Your healthcare provider will do tests to check your kidneys before you receive each dose of LUMOXITI and as needed during treatment. Your healthcare provider may delay your treatment with LUMOXITI if you have severe kidney problems.
  • Infusion reactions. LUMOXITI can cause infusion reactions that are common but can also be serious. Infusion reactions may happen on the day you receive your LUMOXITI infusion. Signs and symptoms of infusion reactions may include:
  • chills
  • cough
  • dizziness
  • shortness of breath or wheezing
  • feeling hot or flushing
  • fast heartbeat
  • headache
  • changes in blood pressure
  • muscle pain
  • nausea
  • fever
  • vomiting

Your healthcare provider may give you medicines to take before and after each LUMOXITI infusion.

  • Electrolyte problems. Tell your healthcare provider if you get any of the following symptoms of electrolyte problems:
  • muscle cramps
  • numbness or tingling
  • abnormal or fast heartbeat
  • nausea
  • seizures

Your healthcare provider will do blood tests to check your electrolytes before you receive each dose of LUMOXITI and during treatment as recommended by your healthcare provider.

Before you receive LUMOXITI, tell your healthcare provider about all your medical conditions, including if you:

  • have had conditions that affect your blood and blood vessels called HUS or severe thrombotic microangiopathy (TMA)
  • have kidney problems
  • are pregnant or plan to become pregnant. LUMOXITI may harm your unborn baby.
    • If you are a female who can become pregnant, you should use effective birth control during treatment with LUMOXITI and for at least 30 days after your last dose of LUMOXITI.
    • If you are a female who can become pregnant, your healthcare provider will perform a pregnancy test before you start treatment with LUMOXITI.
    • Tell your healthcare provider right away if you become pregnant during treatment with LUMOXITI.
  • are breastfeeding or plan to breastfeed. It is not known if LUMOXITI passes into your breast milk. You and your healthcare provider should decide if you will receive LUMOXITI or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LUMOXITI include:

  • swelling in your face, arms, or legs
  • nausea
  • feeling tired
  • headache
  • fever
  • constipation
  • low red blood cells (anemia)
  • diarrhea

These are not all the possible side effects of LUMOXITI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is LUMOXITI?

LUMOXITI is a prescription medicine used to treat adults with hairy cell leukemia (HCL)

  • that has come back or has not responded to previous treatment, and
  • have received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA).

It is not known if LUMOXITI is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNING and Patient Information (Medication Guide).

You may report side effects related to LUMOXITI by calling the Medical Information Call Center 888-501-0998. If you prefer to report these to the FDA, either visit MedWatch or call 1-800-FDA-1088.

LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

LUMOXITI is not recommended in patients with severe renal impairment (CrCl ≤29 mL/min).

IMPORTANT SAFETY INFORMATION

LUMOXITI can cause serious side effects, including:

  • Capillary Leak Syndrome (CLS). LUMOXITI can cause fluid to leak from small blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening if not treated right away. Get emergency medical help right away if you develop any of the following symptoms of CLS:
  • swelling of your face, arms, or legs
  • fast weight gain (increase in 5.5 pounds from Day 1 of your current cycle)
  • weakness or dizziness
  • shortness of breath or trouble breathing
  • cough
  • low blood pressure

Your healthcare provider will check your weight and blood pressure before you receive each dose of LUMOXITI and as needed during treatment.

  • Hemolytic Uremic Syndrome (HUS). Hemolytic uremic syndrome is a condition that affects your blood cells and kidneys and may be life-threatening if not treated right away. Get emergency medical help right away if you develop any of the following symptoms of HUS:
  • decrease in the amount of urine or dark urine (tea-colored)
  • unusual bleeding or bruising of your skin
  • stomach pain
  • vomiting
  • fever
  • feeling tired
  • changes in mood or behavior
  • confusion
  • seizures
  • shortness of breath
  • fast heartbeat

Your healthcare provider will do blood tests to check your blood cells and kidneys before you receive each dose of LUMOXITI and during treatment as recommended by your healthcare provider.

If you develop any of these symptoms of CLS or HUS, your healthcare provider may monitor you in the hospital.

Getting medical treatment right away may help keep these problems from becoming more serious.

Your healthcare provider will check you for these problems during your treatment with LUMOXITI. Your healthcare provider may delay or completely stop treatment with LUMOXITI if you have severe side effects.

LUMOXITI can cause other serious side effects, including:

  • Kidney problems. LUMOXITI may cause kidney problems. People who have HUS, are 65 years of age or older, or those who have kidney problems before starting treatment with LUMOXITI may have an increased risk of worse kidney problems after treatment with LUMOXITI. Tell your healthcare provider right away if you have any changes in the amount you urinate. Your healthcare provider will do tests to check your kidneys before you receive each dose of LUMOXITI and as needed during treatment. Your healthcare provider may delay your treatment with LUMOXITI if you have severe kidney problems.
  • Infusion reactions. LUMOXITI can cause infusion reactions that are common but can also be serious. Infusion reactions may happen on the day you receive your LUMOXITI infusion. Signs and symptoms of infusion reactions may include:
  • chills
  • cough
  • dizziness
  • shortness of breath or wheezing
  • feeling hot or flushing
  • fast heartbeat
  • headache
  • changes in blood pressure
  • muscle pain
  • nausea
  • fever
  • vomiting

Your healthcare provider may give you medicines to take before and after each LUMOXITI infusion.

  • Electrolyte problems. Tell your healthcare provider if you get any of the following symptoms of electrolyte problems:
  • muscle cramps
  • numbness or tingling
  • abnormal or fast heartbeat
  • nausea
  • seizures

Your healthcare provider will do blood tests to check your electrolytes before you receive each dose of LUMOXITI and during treatment as recommended by your healthcare provider.

Before you receive LUMOXITI, tell your healthcare provider about all your medical conditions, including if you:

  • have had conditions that affect your blood and blood vessels called HUS or severe thrombotic microangiopathy (TMA)
  • have kidney problems
  • are pregnant or plan to become pregnant. LUMOXITI may harm your unborn baby.
    • If you are a female who can become pregnant, you should use effective birth control during treatment with LUMOXITI and for at least 30 days after your last dose of LUMOXITI.
    • If you are a female who can become pregnant, your healthcare provider will perform a pregnancy test before you start treatment with LUMOXITI.
    • Tell your healthcare provider right away if you become pregnant during treatment with LUMOXITI.
  • are breastfeeding or plan to breastfeed. It is not known if LUMOXITI passes into your breast milk. You and your healthcare provider should decide if you will receive LUMOXITI or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LUMOXITI include:

  • swelling in your face, arms, or legs
  • nausea
  • feeling tired
  • headache
  • fever
  • constipation
  • low red blood cells (anemia)
  • diarrhea

These are not all the possible side effects of LUMOXITI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is LUMOXITI?

LUMOXITI is a prescription medicine used to treat adults with hairy cell leukemia (HCL)

  • that has come back or has not responded to previous treatment, and
  • have received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA).

It is not known if LUMOXITI is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNING and Patient Information (Medication Guide).

You may report side effects related to LUMOXITI by calling the Medical Information Call Center 888-501-0998. If you prefer to report these to the FDA, either visit MedWatch or call 1-800-FDA-1088.

LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

LUMOXITI is not recommended in patients with severe renal impairment (CrCl ≤29 mL/min).

Read More

AstraZeneca Medicines